← Back to all signals
RESEARCH PAPER ANALYSIS

At What Age Could Screening for Familial Retinoblastoma Be Stopped?: Revised Dutch Retrospective Population-Based Cohort Study 1991-2019.

AI interpretation is pending for this paper.

Open original publication →
PMID40404102
JournalOphthalmology
Publication Date2025-05-20
Ingested2026-08-02 12:04 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

PURPOSE: To determine the latest age at which familial retinoblastoma (Rb) is diagnosed in children screened from birth and to assess the implications for optimizing screening protocols. DESIGN: Retrospective cohort study using nationwide data from the Dutch Rb registry, covering diagnoses from 1991 through 2019. PARTICIPANTS: The study included 38 children with familial Rb, 28 of whom were screened completely from birth according to a standardized protocol, and 10 who were considered incompletely screened. METHODS: Data on genetic testing, screening methods, timing, and age at diagnosis were extracted from medical records at Amsterdam University Medical Center. MAIN OUTCOME MEASURES: Age at diagnosis of familial Rb, categorized by complete versus incomplete screening status. RESULTS: All 28 completely screened children received a diagnosis before 1 year of age, with a median age at diagnosis of 18 days (range, 3-352 days). Sixteen children (57.1%) received a diagnosis at the first examination within the first month after birth, and 82.1% received a diagnosis within the first 6 months. Among 10 incompletely screened children, the median age at diagnosis was 420 days (range, 59 days-4.8 years), with more than half of children receiving a diagnosis after 1 year. CONCLUSIONS: Systematic screening of at-risk children from birth, performed by specialized ophthalmologists and followed by examinations under general anesthesia beginning at a few months of age, resulted in all cases of familial Rb being diagnosed within the first year of life. These findings support an earlier discontinuation of screening than previously recommended. As a result, we revised our screening protocol for a specific subset of at-risk children: those with a low estimated risk (< 3%) of familial Rb are now screened only until the age of 2. The study emphasized the importance of centralized, standardized protocols to optimize screening durations and to reduce health care burdens while maintaining safety for at-risk populations. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Pott's Puffy Tumor Mimicking Langerhans Cell Histiocytosis in a Child. Pediatrics international : official journal of the Japan Pediatric Society 28.5 2 A Population-Based Study of Pediatric and Adult Brainstem Glioma: Prognostic Nomograms for Overall and Cancer-Specific Survival. Turkish neurosurgery 62.02 3 Surgical Management of Third Ventricular Colloid Cysts: The Fate of Open Microsurgery. Turkish neurosurgery 63.5 4 Prenatal Ultrasound and MRI Findings in Two Fetuses With Perineal Lipoma. Congenital anomalies 56.0 5 Undiagnosed Undescended Testis in Young Adults in Saudi Arabia: Examination-Based Prevalence, Sociocultural Barriers to Early Care and Public Health Implications. Arab journal of urology 64.5 6 Neuro-ophthalmological disturbances in pediatric posterior fossa tumors: Prevalence, risk factors, and outcomes. Neuro-oncology advances 63.82 7 The oncology and fertility outcomes in patients with ovarian steroid cell tumors: a single center experience. Journal of ovarian research 57.5 8 Predicting brain tumour enhancement from non-contrast MRI with artificial intelligence: a multicohort, retrospective, diagnostic accuracy study. The Lancet medical imaging & theranostics 59.01 9 Correction: Clinical characteristics and risk factors of acute cutaneous graft-vs.-host disease following allogeneic hematopoietic stem cell transplantation in pediatric acute myeloid leukemia: a singlecenter retrospective study. Frontiers in pediatrics 55.0 10 Targeting IL-23p19 in Inflammatory Bowel Disease: The Road Ahead. Journal of inflammation research 57.65 11 When Three Diseases Collide: Human Immunodeficiency Virus, Hodgkin Lymphoma, and Tuberculosis in a Young Child. Pediatric pulmonology 28.5 12 Late recovery from chronic arginine vasopressin deficiency: a multicenter retrospective case-control study. Journal of the Endocrine Society 58.51 13 Early neuroendocrine signatures of polyendocrine metabolic ovarian syndrome risk: Pubertal programming, social brain signals, and novel therapeutic targets. Journal of neuroendocrinology 62.24 14 Obesity in survivors of childhood cancer. Annals of pediatric endocrinology & metabolism 55.06 15 Risk factors for recurrence in pediatric craniopharyngioma: impact of extensive tumor involvement and growth hormone therapy in a multicenter cohort. Annals of pediatric endocrinology & metabolism 63.36 16 Radiological assessment of radon concentration in drinking water from Lagos State University campus, Nigeria. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 58.7 17 Claudin-3 as a marker of intestinal permeability and its relation to inflammatory status in adolescents with functional gastrointestinal disorders. Pediatric research 63.9 18 Reconstructing the cancer journey: The impact of adolescent and young adult (AYA) patient advisory boards on survivor experiences and advocacy. Journal of psychosocial oncology 57.0 19 Safe electrophysiology-guided resection of an epileptogenic non-exophytic hamartoma at the floor of the fourth ventricle in a child. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 56.4 20 Desire for future children and interest in consultation with a fertility specialist among adolescent and young adult (AYA) cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 57.35 21 Trends in Clinicopathologic Characteristics of Pediatric Differentiated Thyroid Carcinoma: A Single-Center Experience from 1995 to 2022. Endocrinology and metabolism (Seoul, Korea) 56.56 22 Modeling Wilms Tumor Development with Multiple Lineage Human Fetal Kidney Organoids Reveals the Cellular Origin and Specific Drivers of Tumorigenesis. Cancer research 48.5 23 Late effects after novel therapies for childhood cancer: Anticipating the future landscape of health outcomes for survivors. Journal of the National Cancer Institute 65.24 24 Atrophic Papulosis: A Systematic Review of Pediatric Cases. Pediatric dermatology 53.55 25 Menin inhibition in pediatric UBTF-TD myelodysplastic syndrome: molecular rationale and clinical observation. Molecular and cellular pediatrics 63.6 26 Abatacept in biologic-refractory juvenile idiopathic arthritis-associated uveitis: a case-based review. Clinical rheumatology 67.44 27 Paediatric biobanking in the era of precision medicine: ethical, regulatory, and scientific challenges from childhood to adulthood. European journal of pediatrics 53.78 28 Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments). Journal of neuro-oncology 63.57 29 Pediatric and Adult Sinonasal Phosphaturic Mesenchymal Tumors: CDKN2A Copy Number Alterations and Their Association with Recurrence. Head and neck pathology 57.5 30 Systematic review of the impact of germline mutations from unrelated bone marrow donors on post-allogeneic transplantation. Expert review of molecular diagnostics 64.09 31 Efficacy and safety of MEK inhibitors for NF1-associated symptomatic, inoperable plexiform neurofibromas: A systematic review and meta-analysis. PloS one 80.82 32 Eosinophilic angiocentric fibrosis in paediatric IgG4-related disease. BMJ case reports 55.2
PATIENT-FRIENDLY SUMMARY

At What Age Could Screening for Familial Retinoblastoma Be Stopped?: Revised Dutch Retrospective Population-Based Cohort Study 1991-2019.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic